Neuroendocrine marker staining pattern categorization of small‐sized pulmonary large cell neuroendocrine carcinoma
Abstract Background The aim of this study was to identify subgroups with good or bad prognosis in patients with pulmonary large cell neuroendocrine carcinoma (LCNEC) based on immunostaining patterns with neuroendocrine markers and compare them with small cell lung carcinoma (SCLC). Methods From Janu...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-11-01
|
Series: | Thoracic Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1111/1759-7714.13202 |
id |
doaj-45442e08f5e94d8ca92e19f1f768aed8 |
---|---|
record_format |
Article |
spelling |
doaj-45442e08f5e94d8ca92e19f1f768aed82020-11-25T02:20:09ZengWileyThoracic Cancer1759-77061759-77142019-11-0110112152216010.1111/1759-7714.13202Neuroendocrine marker staining pattern categorization of small‐sized pulmonary large cell neuroendocrine carcinomaKazuhiro Minami0Yugo Tanaka1Hiroyuki Ogawa2Naoe Jimbo3Wataru Nishio4Masahiro Yoshimura5Tomoo Itoh6Yoshimasa Maniwa7Division of Thoracic Surgery Kobe University Graduate School of Medicine Kobe City JapanDivision of Thoracic Surgery Kobe University Graduate School of Medicine Kobe City JapanDepartment of Thoracic Surgery Hyogo Cancer Center Akashi City JapanDepartment of Diagnostic Pathology Kobe University Graduate School of Medicine Kobe City JapanDepartment of Thoracic Surgery Hyogo Cancer Center Akashi City JapanDepartment of Thoracic Surgery Hyogo Cancer Center Akashi City JapanDepartment of Diagnostic Pathology Kobe University Graduate School of Medicine Kobe City JapanDivision of Thoracic Surgery Kobe University Graduate School of Medicine Kobe City JapanAbstract Background The aim of this study was to identify subgroups with good or bad prognosis in patients with pulmonary large cell neuroendocrine carcinoma (LCNEC) based on immunostaining patterns with neuroendocrine markers and compare them with small cell lung carcinoma (SCLC). Methods From January 2001 to December 2017, of all patients with resected LCNEC and SCLC, we selected patients whose pathological tumor sizes were ≤30 mm in diameter (defined as small‐sized tumors) and who underwent complete resection with lymphadenectomy. We classified patients with small‐sized LCNEC (sLCNEC) into two subgroups based on immunostaining patterns with three neuroendocrine markers (chromogranin A, synaptophysin, and NCAM) and compared them to small‐sized SCLC (sSCLC). Results A total of 48 patients with sLCNEC and 39 patients with sSCLC were enrolled. Of 48 patients with sLCNEC, 21 were categorized as the small‐sized triple‐positive group (sTP), whose patients were positive for the three neuroendocrine markers, and 27 patients were categorized as the small‐sized nontriple‐positive group (sNTP), whose patients were not positive for all three neuroendocrine markers. The percentage of lymph node metastasis was significantly lower in sNTP than in sTP and sSCLC. There was no significant difference in overall survival, but recurrence‐free survival (RFS) and tumor‐specific survival (TSS) were significantly poorer in sTP and sSCLC than in sNTP. Multivariate analysis revealed sTP and sSCLC were independent prognostic factors for poorer RFS and TSS than those of sNTP. Conclusions The sNTP subgroup had a good prognosis and the sTP subgroup a poor prognosis. There were some similarities in clinicopathological features between sTP and sSCLC.https://doi.org/10.1111/1759-7714.13202Immunostaininglarge cell neuroendocrine carcinomaneuroendocrine markerssmall cell lung carcinomasmall‐sized tumors |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Kazuhiro Minami Yugo Tanaka Hiroyuki Ogawa Naoe Jimbo Wataru Nishio Masahiro Yoshimura Tomoo Itoh Yoshimasa Maniwa |
spellingShingle |
Kazuhiro Minami Yugo Tanaka Hiroyuki Ogawa Naoe Jimbo Wataru Nishio Masahiro Yoshimura Tomoo Itoh Yoshimasa Maniwa Neuroendocrine marker staining pattern categorization of small‐sized pulmonary large cell neuroendocrine carcinoma Thoracic Cancer Immunostaining large cell neuroendocrine carcinoma neuroendocrine markers small cell lung carcinoma small‐sized tumors |
author_facet |
Kazuhiro Minami Yugo Tanaka Hiroyuki Ogawa Naoe Jimbo Wataru Nishio Masahiro Yoshimura Tomoo Itoh Yoshimasa Maniwa |
author_sort |
Kazuhiro Minami |
title |
Neuroendocrine marker staining pattern categorization of small‐sized pulmonary large cell neuroendocrine carcinoma |
title_short |
Neuroendocrine marker staining pattern categorization of small‐sized pulmonary large cell neuroendocrine carcinoma |
title_full |
Neuroendocrine marker staining pattern categorization of small‐sized pulmonary large cell neuroendocrine carcinoma |
title_fullStr |
Neuroendocrine marker staining pattern categorization of small‐sized pulmonary large cell neuroendocrine carcinoma |
title_full_unstemmed |
Neuroendocrine marker staining pattern categorization of small‐sized pulmonary large cell neuroendocrine carcinoma |
title_sort |
neuroendocrine marker staining pattern categorization of small‐sized pulmonary large cell neuroendocrine carcinoma |
publisher |
Wiley |
series |
Thoracic Cancer |
issn |
1759-7706 1759-7714 |
publishDate |
2019-11-01 |
description |
Abstract Background The aim of this study was to identify subgroups with good or bad prognosis in patients with pulmonary large cell neuroendocrine carcinoma (LCNEC) based on immunostaining patterns with neuroendocrine markers and compare them with small cell lung carcinoma (SCLC). Methods From January 2001 to December 2017, of all patients with resected LCNEC and SCLC, we selected patients whose pathological tumor sizes were ≤30 mm in diameter (defined as small‐sized tumors) and who underwent complete resection with lymphadenectomy. We classified patients with small‐sized LCNEC (sLCNEC) into two subgroups based on immunostaining patterns with three neuroendocrine markers (chromogranin A, synaptophysin, and NCAM) and compared them to small‐sized SCLC (sSCLC). Results A total of 48 patients with sLCNEC and 39 patients with sSCLC were enrolled. Of 48 patients with sLCNEC, 21 were categorized as the small‐sized triple‐positive group (sTP), whose patients were positive for the three neuroendocrine markers, and 27 patients were categorized as the small‐sized nontriple‐positive group (sNTP), whose patients were not positive for all three neuroendocrine markers. The percentage of lymph node metastasis was significantly lower in sNTP than in sTP and sSCLC. There was no significant difference in overall survival, but recurrence‐free survival (RFS) and tumor‐specific survival (TSS) were significantly poorer in sTP and sSCLC than in sNTP. Multivariate analysis revealed sTP and sSCLC were independent prognostic factors for poorer RFS and TSS than those of sNTP. Conclusions The sNTP subgroup had a good prognosis and the sTP subgroup a poor prognosis. There were some similarities in clinicopathological features between sTP and sSCLC. |
topic |
Immunostaining large cell neuroendocrine carcinoma neuroendocrine markers small cell lung carcinoma small‐sized tumors |
url |
https://doi.org/10.1111/1759-7714.13202 |
work_keys_str_mv |
AT kazuhirominami neuroendocrinemarkerstainingpatterncategorizationofsmallsizedpulmonarylargecellneuroendocrinecarcinoma AT yugotanaka neuroendocrinemarkerstainingpatterncategorizationofsmallsizedpulmonarylargecellneuroendocrinecarcinoma AT hiroyukiogawa neuroendocrinemarkerstainingpatterncategorizationofsmallsizedpulmonarylargecellneuroendocrinecarcinoma AT naoejimbo neuroendocrinemarkerstainingpatterncategorizationofsmallsizedpulmonarylargecellneuroendocrinecarcinoma AT watarunishio neuroendocrinemarkerstainingpatterncategorizationofsmallsizedpulmonarylargecellneuroendocrinecarcinoma AT masahiroyoshimura neuroendocrinemarkerstainingpatterncategorizationofsmallsizedpulmonarylargecellneuroendocrinecarcinoma AT tomooitoh neuroendocrinemarkerstainingpatterncategorizationofsmallsizedpulmonarylargecellneuroendocrinecarcinoma AT yoshimasamaniwa neuroendocrinemarkerstainingpatterncategorizationofsmallsizedpulmonarylargecellneuroendocrinecarcinoma |
_version_ |
1724873191722057728 |